1 reports of this reaction
1.1% of all POTASSIUM CHLORIDE FOR ORAL SOLUTION reports
#17 most reported adverse reaction
ACUTE MYOCARDIAL INFARCTION is the #17 most commonly reported adverse reaction for POTASSIUM CHLORIDE FOR ORAL SOLUTION, manufactured by Ajenat Pharmaceuticals LLC. There are 1 FDA adverse event reports linking POTASSIUM CHLORIDE FOR ORAL SOLUTION to ACUTE MYOCARDIAL INFARCTION. This represents approximately 1.1% of all 88 adverse event reports for this drug.
Patients taking POTASSIUM CHLORIDE FOR ORAL SOLUTION who experience acute myocardial infarction should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACUTE MYOCARDIAL INFARCTION is a less commonly reported adverse event for POTASSIUM CHLORIDE FOR ORAL SOLUTION, but still significant enough to appear in the safety profile.
In addition to acute myocardial infarction, the following adverse reactions have been reported for POTASSIUM CHLORIDE FOR ORAL SOLUTION:
The following drugs have also been linked to acute myocardial infarction in FDA adverse event reports:
ACUTE MYOCARDIAL INFARCTION has been reported as an adverse event in 1 FDA reports for POTASSIUM CHLORIDE FOR ORAL SOLUTION. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACUTE MYOCARDIAL INFARCTION accounts for approximately 1.1% of all adverse event reports for POTASSIUM CHLORIDE FOR ORAL SOLUTION, making it a notable side effect.
If you experience acute myocardial infarction while taking POTASSIUM CHLORIDE FOR ORAL SOLUTION, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.